(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of 15.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.92%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Theravance Biopharma's revenue in 2025 is $77,205,000.On average, 3 Wall Street analysts forecast TBPH's revenue for 2025 to be $5,994,152,534, with the lowest TBPH revenue forecast at $4,834,684,416, and the highest TBPH revenue forecast at $7,859,887,467. On average, 3 Wall Street analysts forecast TBPH's revenue for 2026 to be $5,795,880,111, with the lowest TBPH revenue forecast at $4,182,505,633, and the highest TBPH revenue forecast at $8,974,886,560.
In 2027, TBPH is forecast to generate $6,029,254,357 in revenue, with the lowest revenue forecast at $5,778,958,716 and the highest revenue forecast at $6,466,894,019.